Immunosuppressive Drug Therapy
Immunosuppressive Drug Therapy
复制标题
DOI：
10.1101/cshperspect.a015487
复制
发表时间：
2013-09-01
影响因子：
5.4
通讯作者：
Suthanthiran, Manikkam
中科院分区：
文献类型：
--
作者：
Hartono, Choli;Muthukumar, Thangamani;Suthanthiran, Manikkam
第一例成功的同卵双胞胎肾移植不需要任何免疫抑制药物。硫唑嘌呤和糖皮质激素的临床应用允许在基因不同的供体和受体之间进行器官移植。移植现在是护理的标准，是器官衰竭患者的救命手术。我们对排斥的免疫生物学的理解的进展已经转化为靶向T细胞、B细胞、浆细胞、共刺激信号、补体产物和抗供体抗体的免疫抑制剂的开发。现代免疫药理学干预有助于移植后观察到的临床成功，但个性化免疫抑制治疗仍存在挑战。
The first successful kidney transplantation between monozygotic identical twins did not require any immunosuppressive drugs. Clinical application of azathioprine and glucocorticosteroids allowed the transfer of organs between genetically disparate donors and recipients. Transplantation is now the standard of care, a life-saving procedure for patients with failed organs. Progress in our understanding of the immunobiology of rejection has been translated to the development of immunosuppressive agents targeting T cells, B cells, plasma cells, costimulatory signals, complement products, and antidonor antibodies. Modern immunopharmacologic interventions have contributed to the clinical success observed following transplantation but challenges remain in personalizing immunosuppressive therapy.